期刊文献+

舒尼替尼联合腹腔镜手术预防胃肠道小间质瘤术后复发临床评价 被引量:4

Sunitinib Combined with Laparoscopy on Recurrence of Small Gastrointestinal Stromal Tumor
下载PDF
导出
摘要 目的探讨舒尼替尼联合腹腔镜手术对胃肠道小间质瘤术后复发情况的影响。方法选取琼海市人民医院2015年至2017年收治的胃肠道小间质瘤患者90例,随机分为观察组和对照组,各45例。两组患者均予腹腔镜手术,观察组患者术后加服苹果酸舒尼替尼胶囊,每次50 mg,每日1次,连续服药4周、停药2周为1个周期,连续治疗3个周期。随访24个月。结果治疗后,观察组患者的癌抗原19-9(CA19-9)、癌胚抗原(CEA)、癌抗原125(CA125)水平及血管内皮生长因子(VEGF)、血小板源生长因子(PDGF)、集落刺激因子-1(CSF-1)水平均明显低于对照组(P<0.05);治疗期间,观察组与对照组不良反应发生率相当(17.78%比11.11%,P>0.05);观察组复发率、远端转移率、再手术率和死亡率均明显低于对照组(P<0.05)。结论舒尼替尼联合腹腔镜手术治疗胃肠道小间质瘤,能明显降低患者肿瘤标志物水平和促血管生成因子水平,降低复发率,远期疗效较好。 Objective To study the effect of sunitinib combined with laparoscopy on the recurrence of small gastrointestinal stromal tumor. Methods A total of 90 patients with small gastrointestinal stromal tumor in the hospital from January 2015 to December 2017 were selected and randomly divided into the observation group and control group,45 cases in each group. Both groups were treated with laparoscopy. After surgery,the observation group was given sunitinib malate capsules,50 mg each time,once a day,for 4 weeks of continuous medication and 2 weeks of withdrawal as 1 cycle;they received continuous treatment of 3 cycles and were followed for 24 months. Results After treatment,the levels of cancer antigen 19-9( CA19-9),carcinoembryonic antigen( CEA),cancer antigen 125( CA125) and vascular endothelial growth factor( VEGF),platelet-derived growth factor( PDGF),colony stimulating factor type 1( CSF-1) in the observation group were significantly lower than those of the control group( P < 0. 05);during the treatment period,the incidence of adverse reactions in the observation group and the control group was equivalent( 17. 78% vs. 11. 11%,P > 0. 05);during the follow-up,the recurrence rate,remote metastasis rate,reoperation rate and mortality rate of the observation group were significantly lower than those of the control group( P < 0. 05). Conclusion Sunitinib combined with laparoscopy for small gastrointestinal stromal tumor can decrease the level of tumor markers and pro-angiogenic factor,reduce the recurrence rate of patients with good long-term efficacy.
作者 梁振雄 黄平 王若天 符敏 宋德鸿 LIANG Zhenxiong;HUANG Ping;WANG Ruotian;FU Min;SONG Dehong(Department of General Surgery,Qionghai People′s Hospital,Qionghai,Hainan,China 571400;The Second District of Gastrointestinal Surgery,Hainan General Hospital,Haikou,Hainan,China 571100)
出处 《中国药业》 CAS 2020年第16期85-87,共3页 China Pharmaceuticals
基金 海南省重点研发计划项目[ZDYF2018152]。
关键词 胃肠道小间质瘤 腹腔镜手术 舒尼替尼 肿瘤标志物 复发率 gastrointestinal small stromal tumor laparoscopy sunitinib tumor markers recurrence rate
  • 相关文献

参考文献8

二级参考文献56

  • 1杨其昌,季晓华,沈屹,韩枋,张晓娟,刘宏斌.74例胃肠道间质瘤临床病理与生物学行为评价[J].中华病理学杂志,2005,34(1):6-10. 被引量:68
  • 2何裕隆.胃肠间质瘤的流行病学研究现状及其治疗[J].中华胃肠外科杂志,2007,10(1):8-10. 被引量:16
  • 3Rubin BP,Heinrich MC,Corless CL.Gastrointestinal stromal tumour.Lancet,2007,369(9574):1731-1741.
  • 4Blanke CD,Demetri GD,von Mehren M,et al.Long-term results from a randomized phase Ⅱ trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol,2008,26(4):620-625.
  • 5Oken MM,Creech RH,Tormey DC,et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol,1982,5:649-655.
  • 6Gold JS,van der Zwan SM,G(o)nen M,et al.Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.Ann Surg Oncol,2007,14(1):134-142.
  • 7Blanke CD,Rankin C,Demetri GD,et al.Phase Ⅲ randomized,intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase:S0033.J Clin Oncol,2008,26 (4):626-632.
  • 8Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial.Lancet,2006,368(9544):1329-1338.
  • 9Reichardt P,Kang Y,Ruka W,et al.Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatmentuse trial of patients with advanced GIST.J Clin Oncol,2008,26suppl:10548.
  • 10Raut CP,Posner M,Desai J,et al.Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.J Clin Oncol,2006,24(15):2325-2331.

共引文献158

同被引文献46

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部